Novocell Becomes ViaCyte, a Pre-Clinical Diabetes Stem Cell Developer
ViaCyte, Inc is the new name for Novocell, a preclinical stage stem cell company. ViaCyte is a preclinical therapeutic company focused on diabetes based on pancreatic beta cell progenitors (Pro-Islet™) derived from human pluripotent stem cells. These cells are implanted using a durable and retrievable encapsulation device. Once implanted and matured, these cells secrete insulin in response to blood glucose levels. ViaCyte’s goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.
The name ViaCyte was previously used by ViaCell, Inc., but their use was discontinued following acquisition of ViaCell by Perkin Elmer and acquired all rights to the ViaCyte service marks and internet domain name addresses previously owned by ViaCell.
ViaCyte is funded in part through the support of the California Institute for Regenerative Medicine.
